prostate cancer

[Prostate] Scientists investigated a possible role for protease-activated receptor-2 in regulating the behavior of bone cells exposed to metastatic prostate cancer cells.

[European Journal of Pharmacology] The authors discuss the therapeutic potential of p53-reactivating compounds with a particular focus on the pharmacological rescue of p53 in metastatic prostate cancer.

[AstraZeneca] Positive results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival versus current standard-of-care abiraterone as a 1st-line treatment for patients with metastatic CRPC.

[Biophysical Journal] Investigators noted that circulating tumor cells isolated from prostate cancer patients displayed a specific mechanical phenotype, determined with atomic force microscopy: high softness and high adhesion.

[Laboratory Investigation] Silencing LINC01963 inhibited TrkB protein level to enhance the chemosensitivity of PC3-DR to docetaxel by means of competitively binding to miR-216b-5p.

[Prostate Cancer and Prostatic Diseases] Researchers examined myokine levels of serum acquired from metastatic CRPC patients recruited to the INTERVAL-GAP4 trial before and after six months of exercise and its tumour-suppressive effect.